Antibe Therapeutics Inc(Pre-Merger) ATBPF

2021 Year End Financial Results

[GameChangerBet]

https://www.businesswire.com/news/home/20210628005228/en/Antibe-Therapeutics-Reports-2021-Year-End-Financial-Results-and-Business-Highlights

[Forestview]

Financials look strong.  Good summary.  Exciting times ahead.  

[RalphRalph]

Some good for sure, but there are some concerning aspects as well.  Note the P3 delay.  Also, why has 352 not progressed further?  It's perplexing that amidst all other initiatives, they've not been able to advance 352.  Before they add more preclinical IP to the pipeline (especially in crowded areas like IBD & Alzheimer's), perhaps they could focus on

[MrMugsy]

RalphRalph ... will try to add to your comments.  My opinion only. I think we call all agree that things are happening very quickly now.  Some things become more important while others become less important.  Constantly in flux and likely going change even faster going forward. For example, looks like Dan is saying Q1 2022 for the trial but he also said (at Raymond James) that he

[woundedknee]

Quit defecting and spinning your own narritive Mugsy. P3 was supposed to be this fall and also not a mention of Nasdaq, so you can kick that can down the road as well. So those of us highly invested here have at least another year to wait. I'll wait as I have little choice. We'll see how the market reacts to this. cheers and gl

[MrMugsy]

Put it another way Wounded - no matter what the timing is  - you are going to live with it.  That's really all there is to that. Second - why are you worried about the timing today - didn't seem to bug you when it came out at Raymond James? You can try to micro-manage the timing all you want - you're going no where fast.

[woundedknee]

Can't stand real criticism can you mugs> You're nothing but a mouthpiece for Dan and his broken promises and lack of transparency. How much is he paying you? And what's this about timing? Again, my target on this is 5 bucks and if I'm so lucky for it to get there I'm gone. You'll see how fast I go no where.

[MrMugsy]

Wounded - don't get salty towards me just because your unhappy. I really don't care about your feelings. Don't try to rain on my parade ! : )

[123ABC]

Mugsy likes red parades lol

[woundedknee]

There'll be lots of rain on your parade Mugsy. Seeing that the January update listed the phase 3 initiation in the second half of 2021 and now it goes to 1st Q of 2022. That's a fairly substantial delay as it could mean as much as 9 months. Of course that's if Dan is being upfront with us this time. As I've stated in the past I commend all those (including Dan) that have put in the

[MrMugsy]

You can complain all you want Wounded but if you have a problem with Dan - go see Dan. Ask him about his ethics. Leaving the personal attacks to those already on ignore. --------------------------- Anyway ... what do we really know at this time ? That's all I care about.  - AME studies begin the week of July 5 and are expected to end in Q4. - Completion of single-dose IND-opening study

[woundedknee]

I have nothing but praise for the work Dan has done, other than his obvious disregard for his shareholders. Of course that is jmo.

[woundedknee]

And don't take my word for it..the market is speaking

[RalphRalph]

Your assumptions about how Big Pharma values a pipeline/platform are misinformed.  I strongly doubt that Big Pharma cares about preclinical IP in areas that are already crowded with competition.  A company proves its platform to Big Pharma by advancing molecules through the clinic and providing validated clinical trial data - not by amassing a bunch of preclinical/discovery IP. 

[WalkOverTheStrt]

RalphRalph 100% agree... the fact some posters believe that preclincial means anything to valuations is frankly scary... To be a broken record - I've stated this multiple times... Antibe needs to bring another drug to human trials as fast as possible to show HS2 is a platform. Until then this biotech has one drug and NOT a platform. This isn't some high level concept. This is biotech